Literature DB >> 25209557

Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.

Xiao-Dong Cheng1, Liu-Wei Song2, Lin-Lin Fang2, Lin Yang2, Yong Wu2, Sheng-Xiang Ge2, Quan Yuan3, Jun Zhang2, Ning-Shao Xia2, Xiao-Ke Hao4.   

Abstract

Hepatitis B surface antigen (HBsAg) quantification has garnered attention because of its high predictive value in determining treatment responses. The HBsAg quantification assays, such as Architect and Elecsys, are commercially available, and more assays are in development. We aimed to compare the results of the Architect and Elecsys assays with those of a new assay, WTultra. The WTultra HBsAg assay is a sandwich chemiluminescent microplate enzyme immunoassay and provides an alternative choice which is more cost-effective and potentially applicable in developing or resource-constrained countries and areas. A total of 411 serum samples were collected from patients during various phases of chronic hepatitis B (CHB) infection. The samples were assessed using the three assays, and the results were compared and analyzed. The results for the Architect, Elecsys, and WTultra assays were well correlated according to the overall results for the samples (correlation coefficients, rArchitect versus WTultra = 0.936, rArchitect versus Elecsys = 0.952, and rWTultra versus Elecsys = 0.981) and the various infection phases (rArchitect versus WTultra ranging from 0.67 to 0.975, rArchitect versus Elecsys ranging from 0.695 to 0.982, and rWTultra versus Elecsys ranging from 0.877 to 0.99). Additionally, consistent results were observed according to genotype (genotype B: rArchitect versus WTultra = 0.976, rArchitect versus Elecsys = 0.978, and rWTultra versus Elecsys = 0.979; genotype C: rArchitect versus WTultra = 0.950, rArchitect versus Elecsys = 0.963, and rWTultra versus Elecsys = 0.981) and hepatitis B virus (HBV) DNA levels (rArchitect = 0.540, rWTultra = 0.553, and rElecsys = 0.580). In conclusion, the Elecsys and WTultra assays were well correlated with the Architect assay, irrespective of the CHB infection phase or genotype. All of these assays are reliable for HBsAg quantification.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25209557      PMCID: PMC4248759          DOI: 10.1128/CVI.00529-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.

Authors:  Karsten Wursthorn; Jerzy Jaroszewicz; Behrend J Zacher; Martina Darnedde; Regina Raupach; Ingmar Mederacke; Markus Cornberg; Michael P Manns; Heiner Wedemeyer
Journal:  J Clin Virol       Date:  2011-01-26       Impact factor: 3.168

2.  Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.

Authors:  Matsuo Deguchi; Naoko Yamashita; Masanori Kagita; Seishi Asari; Yoshinori Iwatani; Takahiko Tsuchida; Kazushige Iinuma; Isa K Mushahwar
Journal:  J Virol Methods       Date:  2004-02       Impact factor: 2.014

3.  Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

Authors:  Tin Nguyen; Alexander J V Thompson; Scott Bowden; Catherine Croagh; Sally Bell; Paul V Desmond; Miriam Levy; Stephen A Locarnini
Journal:  J Hepatol       Date:  2010-02-16       Impact factor: 25.083

4.  Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Tung-Hung Su; Chia-Chi Wang; Chi-Ling Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

5.  Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

Authors:  Jerzy Jaroszewicz; Beatriz Calle Serrano; Karsten Wursthorn; Katja Deterding; Jerome Schlue; Regina Raupach; Robert Flisiak; C-Thomas Bock; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

Review 6.  Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Authors:  Henry Lik-Yuen Chan; Alex Thompson; Michelle Martinot-Peignoux; Teerha Piratvisuth; Markus Cornberg; Maurizia Rossana Brunetto; Hans L Tillmann; Jia-Horng Kao; Ji-Dong Jia; Heiner Wedemeyer; Stephen Locarnini; Harry L A Janssen; Patrick Marcellin
Journal:  J Hepatol       Date:  2011-06-28       Impact factor: 25.083

7.  Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.

Authors:  Karsten Wursthorn; Mechthild Jung; Antonio Riva; Zachary D Goodman; Patricia Lopez; Weibin Bao; Michael P Manns; Heiner Wedemeyer; Nikolai V Naoumov
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

8.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Authors:  Yun-Fan Liaw; Jia-Horng Kao; Teerha Piratvisuth; Henry Lik Yuen Chan; Rong-Nan Chien; Chun-Jen Liu; Ed Gane; Stephen Locarnini; Seng-Gee Lim; Kwang-Hyub Han; Deepak Amarapurkar; Graham Cooksley; Wasim Jafri; Rosmawati Mohamed; Jin-Lin Hou; Wan-Long Chuang; Laurentius A Lesmana; Jose D Sollano; Dong-Jin Suh; Masao Omata
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

9.  Global programme for control of hepatitis B infection.

Authors:  M Kane
Journal:  Vaccine       Date:  1995       Impact factor: 3.641

Review 10.  Predictors of treatment response in chronic hepatitis B.

Authors:  Grace L-H Wong; Henry L-Y Chan
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.